Management of human cytomegalovirus infection in transplantation: Validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection

New Microbiologica

Volumn 34, Issue 3, 2011, Pages 229-254

  Gerna, Giuseppe ^a   Lilleri, Daniele ^a   Furione, Milena ^a   Baldanti, Fausto ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

CD4 + T cells; CD8 + T cells; Hematopoietic stem cell transplant; Human cytomegalovirus; Immunological cut off; Pre emptive therapy; Solid organ transplant; Viral load cut off

Indexed keywords

ANTIVIRUS AGENT;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; REVIEW; TRANSPLANTATION; VIROLOGY;

ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTS;

HUMAN HERPESVIRUS 5;

EID: 84860390349     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (175)

1. Asberg A., Humar A., Jardine A.G., Rollag H., Pescovttz M.D., Mouas H., et al. (2009). Long-term outcomes of CMV disease treatment with valgan- ciclovir versus IV ganciclovir in solid organ transplant recipients. Am. J. Transplant. 9, 1205-1213.
2. Arthurs S.K., Eid A.J., Pedersen R.A., Kremers W.K., Cosío EG., Patel R, et al. (2008). Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin. Infect. Dis. 46, 840-846. (Pubitemid 351417184)
3. Baldanti F., Zavattoni M., Sarasini A., Gatti M., Chezzi L., Gerna G. (1997). Comparative quantification of human cytomegalovirus DNA in blood of immunocompromised patients by PCR and Murex Hybrid Capture System. Clin. Diagn. Virol. 8, 159-165. (Pubitemid 27397839)
4. Baldanti F., Simoncini L., Sarasini A., Zavattoni M., Grossi P., Revello M.G., et al. (1998). Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation. 66, 324-329. (Pubitemid 28390213)
5. Baldanti F., Lilleri D., Campanini G., Comolli G., Ridolfo A.L., Rusconi S., et al. (2004). Human cytomegalovirus double resistance in a donor-posi- tive/recipient-negative lung transplant patient withan impaired CD4-mediated specific immune response. J. Antimicrob. Chemother. 53, 536-539. (Pubitemid 38380258)
6. Benmarzouk-Hidalgo O.J., Cisneros J.M., Cordero E., Martín- Peña A., Sanchez E., Martin-Gandul C., et al. (2011). Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation. 91, 927-933.
7. Boeckh M., Ljungman P.L. (1998). Cytomegalovirus infection after bone marrow transplantation, In Transplant Infection, Paya C. (Ed.) Lippincot-Raven Philadelphia, PA, USA. 215-227.
8. Boeckh M. (1999). Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl. Infect. Dis. 1, 165-178.
9. Boeckh M., Bowden R.A., Storer B., Chao N.J., Spielberger R., Tierney D.K., et al. (2001). Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal an-tibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 7, 343-351. (Pubitemid 32677436)
10. Boeckh M., Leisenring W., Riddell S.R., Bowden R.A., Huang M.L., Myerson D., et al. (2003). Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 101, 407-414. (Pubitemid 36077556)
11. Boehme K.W., Compton T. (2004). Innate sensing of viruses by toll-like receptors. J. Virol. 78, 7867-7873. (Pubitemid 38944272)
12. Boehme K.W., Guerrero M., Compton T. (2006). Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. 7. Immunol. 177, 7094-7102. (Pubitemid 44715077)
13. Boppana S.B., Britt W.J. (1995). Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J. Infect. Dis. 171, 1115-1121.
14. Britt W.J., Vugler L., Butfiloski E.J., Stephens E.B. (1990). Cell surface expression of human cy-tomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. 7. Virol. 6, 1079-1085. (Pubitemid 20087744)
15. Bukowski J.E, Warner J.F., Dennert G., Welsh R.M. (1985). Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J. Exp. Med. 161, 40-52. (Pubitemid 15169719)
16. Caliendo A.M., St George K., Allega J., Bullotta A.C., Gilbane L., Rinaldo C.R. (2002). Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays. J. Clin. Microbiol. 40, 1581-1586. (Pubitemid 34493123)
17. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187, 1395-1402. (Pubitemid 28215399)
18. +T lymphocytes with cellular maturation. J. Exp. Med. 203, 2865-2877. (Pubitemid 46026164)
19. Chatterjee A., Harrison C.J., Britt W.J., Bewtra C. (2001). Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein B antibody transfer in guinea pigs. J. Infect. Dis. 183, 1547-1553. (Pubitemid 32466691)
20. Chemaly R.E, Yen-Lieberman B., Chapman J., Reilly A., Bekele B.N., Gordon S.M., et al. (2005). Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am. J. Transplant. 5, 544-548. (Pubitemid 40313346)
21. Cortez K.J., Fischer S.H., Fahle G.A., Calhoun L.B., Childs R.W., Barrett A.J., et al. (2003). Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem- cell transplant recipients. J. Infect. Dis. 188, 967- 972. (Pubitemid 37268245)
22. + T cells specific for glycoprotein B from cytomegalovirus exhibit extreme conservation of T-cell receptor usage between different individuals. Blood. 111, 2053-2061. (Pubitemid 351451517)
23. Crough T., Burrows J.M., Fazou C., Walker S., Davenport M.P., Khanna R. (2005). Contemporaneous fluctuations in T cell responses to persistent herpes virus infections. Eur. J. Immunol. 35, 139-149. (Pubitemid 40123860)
24. Crough T., Fazou C., Weiss J., Campbell S., Davenport M.P., Bell S.C., et al. (2007). Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T-cell response. J. Virol. 81, 11538-11542. (Pubitemid 47536125)
25. Crough T., Khanna R. (2009). Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 22, 76-98.
26. + T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus: human cytomegalovirus. J. Immunol. 179, 3203-3213.
27. Delale T., Paquin A., Asselin-Paturel C., Dalod M., Brizard G, Bates E.E., et al. (2005). MyD88-dependent and -independent murine cytomegalovirus sensing for IFN-alpha release and initiation of im-mune responses in vivo. J. Immunol. 175, 6723- 6732. (Pubitemid 41598916)
28. Eid A.J., Bakri S.J., Kìjpittayarit S., Razonable R.R. (2008). Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl. Infect. Dis. 10, 13-18. (Pubitemid 351171315)
29. Einsele H., Ehninger G., Hebart H., Wittkowski K.M., Schuler ÍJ., Jahn G., et al. (1995). Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 86, 2815-2820.
30. Einsele H., Roosnek E, Rufer N., Sinzger C, Riegler S., Löffler J., et al. (2002). Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 99, 3916-3922. (Pubitemid 35332029)
31. Elkington R., Shoukry N.H., Walker S., Crough T., Fazou C., Kaur A., et al. (2004). Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur. J. Immunol. 34, 3216-3226. (Pubitemid 39549400)
32. Emery V.C., Sabin C.A., Cope A.V., Gor D., Hassan-Walker A.F., Griffiths P.D. (2000). Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 355, 2032-2036. (Pubitemid 30339241)
33. Erice A., Borrell N., Li W, Miller W.J., Balfour H.H. Jr. (1998). Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J. Infect. Dis. 178, 531-534. (Pubitemid 28347939)
34. Fishman J.A., Rubin R.H. (1998). Infection in organ-transplant recipients. N. Engl. J. Med. 338, 1741- 1751. (Pubitemid 28268592)
35. +T- cell responses using the QuantiFERON®-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J. Med. Virol. 82, 433-440.
36. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T.J., Alford C.A. (1992). The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326, 663-667.
37. Freyer J.F., Heath A.B., Anderson R., Minor P.D., And the Collaborative Study Group. (2010). Collaborative study to evaluate the proposed 1st WHO International Standard for human cy-tomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. WHO/BS/10.2138, pp. 1- 40. Geneva, 18-22 Oct. 2010.
38. + T cells in protec-tion against CMV disease. Blood. 101, 2686-2692. (Pubitemid 36857631)
39. +/CD8"'+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T- cell stimulation origin. Blood. 109, 4890-4898. (Pubitemid 46827786)
40. Gerna G., Revello M.G., Percivalle E., Zavattoni M., Parea M., Battaglia M. (1990). Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. J. Clin. Microbiol. 28, 2681-2688.
41. Gerna G., Zipeto D., Parea M., Revello M.G., Silini E., Percivalle E., et al. (1991). Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia and DNAemia. J. Infect. Dis. 164, 488-498.
42. Gerna G., Revello M.G., Percivalle E., Morini F. (1992). Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J. Clin. Microbiol. 30, 1232-1237.
43. Gerna G., Baldanti F., Sarasini A., Furione M, Percivalle E., Revello M.G., et al. (1994a). Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in pe-ripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV re-tinitis. Antimicrob. Agents Chemother. 38, 38-44. (Pubitemid 24018154)
44. Gerna G., Furione M., Baldanti F., Sarasini A. (1994b). Comparative quantitation of human cy-tomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J. Clin. Microbiol. 32, 2709-2717. (Pubitemid 24319108)
45. Gerna G., Percivalle E., Torsellini M., Revello M.G. (1998a) Standardization of the human cy-tomegalovirus antigenemia assay by means of in vitro-generated pp65-positive peripheral blood polymorphonuclear leukocytes. J. Clin. Microbiol. 36, 3585-3589. (Pubitemid 28533233)
46. Gerna G., Zavattoni M., Baldanti F., Sarasini A., Chezzi L., Grossi P., et al. (1998b). Human cy-tomegalovirus (HCMV) leukoDNAemia correlates more closely with clinical symptoms than antigen-emia and viremia in heart and heart-lung transplant recipients with primary HCMV infection. Transplantation. 65, 1378-1385. (Pubitemid 28283102)
47. Gerna G., Baldanti F., Middeldorp J.M., Furione M., Zavattoni M, Lilleri D., et al. (1999). Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification. J. Clin. Microbiol. 37, 902-911. (Pubitemid 29140587)
48. Gerna G., Baldanti F., Grossi P., Locatelo F., Colombo P., Viganò M., et al. (2001). Diagnosis and monitoring of human cytomegalovirus infection in transplant recipients. Rev. Med. Microbiol. 12, 155-175. (Pubitemid 32661486)
49. Gerna G., Baldanti F., Lilleri D, Parea M., Torsellini M., Castiglioni B., et al. (2003a). Human cy-tomegalovirus pp67 mRNAemia Vs. pp65 antigenemia in heart and lung transplant recipients: a prospective randomized controlled open-label trial. Transplantation. 75, 1012-1019. (Pubitemid 36438531)
50. Gerna G., Lilleri D., Baldanti F., Torsellini M., Giorgiani G., Zecca M., et al. (2003b). Human cy-tomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood. 101, 5053- 5060. (Pubitemid 36857773)
51. Gerna G., Sarasini A., Lilleri D, Percivalle E., Torsellini M., Baldanti F., et al. (2003c). In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients. J. Infect. Dis. 188, 1639-1647. (Pubitemid 38010673)
52. Gerna G., Lilleri D., Zecca M., Alessandrino E.P., Baldanti F., Revello M.G., et al. (2005a). Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica. 90, 526-533. (Pubitemid 40592896)
53. +T cells. J. Gen. Virol. 86, 275-284. (Pubitemid 40227938)
54. Gerna G., Lilleri D. (2006). Monitoring transplant patients for human cytomegalovirus: diagnostic update. Herpes. 13, 4-11. (Pubitemid 43900947)
55. + T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant. 6, 2356-2364. (Pubitemid 44359421)
56. Gerna G., Baldanti F., Torsellini M., Minoli L., Viganò M., Oggionni T., et al. (2007). Evaluation of human cytomegalovirus DNAemia vs pp65-anti- genemia cutoff for guiding preemptive therapy in transplant recipients: A randomized study. Antivir. Ther. 12, 63-72. (Pubitemid 46340427)
57. Gerna G., Lilleri D., Callegaro A., Goglio A., Cortese S., Stroppa P., et al. (2008a). Prophylaxis followed by preemptive therapy vs preemptive therapy for prevention of human cytomegalovirus disease inpediatrie patients undergoing liver transplantation. Transplantation. 86, 163-166.
58. Gerna G., Lilleri D., Caldera D, Furione M., Zenone Bragotti L., Alessandrino E.P. (2008b). Validation of a DNAemia cut-off for pre-emptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 41, 873-879. (Pubitemid 351766594)
59. Gerna G, Lilleri D., Rognoni V., Agozzino M., Meloni F., Oggionni T., et al. (2009). Preemptive therapy of systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am. J. Transplant. 9, 1142-1150.
60. Gillespie G.M., Wills M.R., Appay V., O'callaghan C., Murphy M, Smith N., et al. (2000). Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J. Virol. 74, 8140-8150. (Pubitemid 30642582)
61. Gleaves C.A., Smith T.F., Shuster E.A., Pearson G.R. (1984). Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugádon and monoclonal antibody to an early antigen. J. Clin. Microbiol. 19, 917-919. (Pubitemid 14105054)
62. + T lymphocytes in T-cell-de- pleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood. 98, 1358-1364.
63. Gratama J.W., Boeckh M., Nakamura R, Cornelissen J.J., Brooimans R.A., Zaia J.A., et al. (2010). Immune monitoring with iTAg MHC Tetramere for prediction of recurrent or persistent cy-tomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood. 116, 1655- 1662.
64. Grossi P., Minoli L., Percivalle E., Irish W, Viganò M., Gerna G. (1995). Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation. 59, 847-851.
65. Hadaya K., De Rham C., Bandelier C., Bandelier C., Ferrari-Lacraz S., Jendly S., et al. (2008). Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am. J. Transplant. 8, 2674-2683.
66. Hahn G., Revello M.G., Patrone M., Percivalle E., Campanini G., Sarasini A., et al. (2004). Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 78, 10023-10033. (Pubitemid 39187120)
67. Hakki M., Riddell S.R., Storek J., Carter R.A., Stevens-Ayers T., Sudour P., et al. (2003). Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 102, 3060-3067. (Pubitemid 37248884)
68. Hamprecht K., Steinmassl M., Einsele H., Jahn G. (1998). Discordant detection of human cy-tomegalovirus DNA from peripheral blood mononuclear cells, granulocytes and plasma: correlation to viremia and HCMV infection. J. Clin. Virol. 11, 125-136. (Pubitemid 28462064)
69. Hebart H., Gamer D., Loeffler J., Mueller C., Sinzger C., Jahn G., et al. (1998). Evaluation of Murex CMV DNA hybrid capture assay for detection and quantitation of cytomegalovirus infection in patients following allogeneic stem cell transplantation. J. Clin. Microbiol. 36, 1333-1337. (Pubitemid 28208022)
70. Hebart H, Brugger W, Grigoleit U., Gscheidle B., Loeffler J., Schäfer H., et al. (2001). Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood. 97, 2183-2185. (Pubitemid 32239107)
71. Hebart H., Daginik S., Stevanovic S., Grigoleit U, Dobler A., Baur M., et al. (2002). Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon- gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood. 99, 3830-3837. (Pubitemid 34534558)
72. Humar A., Gregson D., Caliendo A.M., Mcgeer A., Malkan G., Krajden M., et al. (1999). Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation. 68, 1305-1311.
73. Humar A., Snydman D., and the AST. (2009). Cytomegalovirus in solid organ transplant recipi-ents. Am. J. Transplant. 9 (Suppl. 4), S78-86.
74. + T lymphocytes. J. Virol. 64, 5457-5464. (Pubitemid 20364538)
75. Jonjic S., Pavic I., Polic B., Crnkovic I., Lucin P., Koszinowski U.H. (1994). Antibodies are not es-sential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179, 1713-1717. (Pubitemid 24129592)
76. Karrer U., Sierro S., Wagner M., Oxenius A., Hengel H., Koszinowski U.H., et al. (2003). Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J. Immunol. 170, 2022-2029. (Pubitemid 36197423)
77. Kelly D.A. (2006). Current issues in pediatric transplantation. Pediatr. Transplant. 10, 712-720. (Pubitemid 44186294)
78. Khan N., Shariff N., Cobbold M., Bruton R., Ainsworth J.A., Sinclair A.J., et al. (2002). Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J. Immunol. 169, 1984-1992. (Pubitemid 34857662)
79. Khan N., Hislop A., Gudgeon N., Cobbold M., Khanna R., Nayak L., et al. (2004). Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J. Immunol. 173, 7481-7489. (Pubitemid 39628188)
80. Khoury J. A., Storch G.A., Bohl D.L., Schuessler R.M., Torrence S.M., Lockwood M., et al. (2006). Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am. J. Transplant. 6, 2134-2142.
81. Klenovsek K., Weisel F., Schneider A., Appelt U., Jonjic S., Messerle M., et al. (2007). Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood. 110, 3472-3479. (Pubitemid 350106344)
82. Kliem V., Fricke L., Wollbrink T., Burg M., Radermacher J., Rohde F. (2008). Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am. J. Transplant. 8, 975-983. (Pubitemid 351537752)
83. Knight A., Madrigal A.J., Grace S., Sivakumaran J., Kottaridis P., MacKinnon S., et al. (2010). The role of Vò2-negative yò T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood. 116, 2164-2172.
84. Kolberg J., Miner R., Hoo B., et al. (1996). Development of a branched DNA signal amplifica-tion assay to monitor patients on anti-CMV therapies. Biologicals. 24, 216.
85. Kotton C.N., Kumar D., Caliendo A.M., Âsberg A., Chou S., Snydman D.R., Allen U., Humar A.; on behalf of the Transplantation Society International CMV Consensus Group. (2010). International Consensus Guideliness on the Management of cytomegalovirus in solid organ transplantation. Transplantation. 89, 779-795.
86. Krause H., Hebart H., Jahn G., Müller C.A., Einsele H. (1997). Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant. 19, 1111-1116. (Pubitemid 27267735)
87. Kumar D., Chernenko S., Moussa G., Cobos I., Manuel O., Preiksaitis J., et al. (2009). Cell-mediated immunity to predict cytomegalovirus disease in high- risk solid organ transplant recipients. Am. J. Transplant. 9, 1214-1222.
88. Kusne S., Grossi P., Irish W., St George K., Rinaldo C., Rakela J., et al. (1999). Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation. 68, 1125-1131. (Pubitemid 29517701)
89. Lacey S.F., La Rosa C., Zhou W., Sharma M.C., Martinez J., Krishnan A., et al. (2006). Functional comparison of T cells recognizing cytomegalovirus pp65 and immediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J. Infect. Dis. 194, 1410-1421. (Pubitemid 44706510)
90. Lafarge X., Merville P., Cazin M.C., Bergé F., Potaux L., Moreau J.F., et al. (2001). Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role. J. Infect. Dis. 184, 533-541. (Pubitemid 32783542)
91. Lautenschlager I., Halme L., Höckerstedt K., Krogerus L., Taskinen E. (2006). Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl. Infect. Dis. 8, 21-30.
92. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., Riddell S.R. (1994). Recovery of HLA-restricted cytomegalovirus (CMV)-specifìc T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 83, 1971-1979. (Pubitemid 24107924)
93. Li H., Dummer J.S., Estes W.R., Meng S., Wright P.F., Tang Y.W. (2003). Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J. Clin. Microbiol. 41, 187-191. (Pubitemid 36098574)
94. Lilleri D., Baldanti F., Gatti M., Rovida F., Dossena L., De Grazia S., et al. (2004). Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy of human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. J. Med. Virol. 73, 412- 418. (Pubitemid 38685749)
95. + T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood. 108, 1406-1412. (Pubitemid 44232045)
96. Lilleri D., Gerna G., Furione M., Bernardo M.E., Giorgiani G., Telli S., et al. (2007a). Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of pre-emptively treated children and young adults receiving hematopoietic stem cell transplantation compared with qualitative pp65 antigenemia. Blood. 110, 2757-2760. (Pubitemid 47523202)
97. Lilleri D., Zelini P., Fornara C., Comolli G., Gerna G. (2007b). Inconsistent responses of cy-tomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant re-cipients. Am. J. Transplant. 7, 1997-2005. (Pubitemid 47038000)
98. + T-cell re- constitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica. 93, 248-256. (Pubitemid 351397713)
99. + T cell differentiation after primary infection. J. Infect. Dis. 198, 536-543.
100. Lilleri D., Gerna G., Fornara C., Chiesa A., Comolli G., Zecca M., et al. (2009a). Human cy-tomegalovirus-specific T-cell reconstitution in young patients receiving T-cell-depleted, allogeneic hematopoietic stem cell transplantation. J. Infect. Dis. 199, 829-836.
101. Lilleri D., Lazzarotto T., Ghisetti V., Ravanini R, Capobianchi M.R., Baldanti F., et al. (2009b). Multicenter quality control study for human cytomegalovirus DNAemia quantification. New Microbiol. 32, 245-253.
102. +T-cell responses in primary infection of the immunocompetent and immunocompromised host. Clin. Immunol. 131, 395-403.
103. Limaye A.R, Bowden R.A., Myerson D, Boeckh M. (1997). Cytomegalovirus disease occurring before engraftment in marrow transplant recipients. Clin. Infect. Dis. 24, 830-835. (Pubitemid 27193862)
104. Limaye A.P., Bakthavatsalam R., Kim H.W., Kühr C.S., Halldorson J.B., Healey P.J., et al. (2004). Late- onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation. 78, 1390-1396. (Pubitemid 39507981)
105. Limaye A.P., Bakthavatsalam R., Kim H.W., Randolph S.E., Halldorson J.B., Healey P.J., et al. (2006). Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation. 81, 1645-1652. (Pubitemid 43948296)
106. Ljungman P., Engelhard D., Link H., Biron P., Brandt L., Brunet S., et al. (1992). Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin. Infect. Dis. 14, 831-835.
107. Ljungman P., Aschan J., Lewensohn-Fuchs I., Carlens S., Larsson K, Lönnqvist B., et al. (1998a). Results of different strategies for reducing cytomegalovirus- associated mortality in allogeneic stem cell transplant recipients. Transplantation. 66, 1330-1334. (Pubitemid 28551015)
108. Ljungman P., Cordonnier C., Einsele H., Bender-Götze C., Bosi A., Dekker A., et al. (1998b). Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 21, 473-476. (Pubitemid 28107954)
109. Ljungman P., Griffiths P., Paya C. (2002). Definitions of cytomegalovirus infection and disease in transplant recipients. Clin. Infect. Dis. 34, 1094-1097. (Pubitemid 34289682)
110. Locatelli F., Percivalle E., Comoli P., Maccario R., Zecca M., Giorgiani G., et al. (1994). Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone marrow transplanta-tion: role of early antiviral treatment for HCMV an-tigenemia on patients' outcome. Brit. J. Haematol. 88, 64-71. (Pubitemid 24293854)
111. + T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur. J. Immunol. 35, 1795-1804. (Pubitemid 40862327)
112. Macagno A., Bernasconi N., Vanzetta F., Dander E., Sarasini A., Revello M.G., ET AL. (2010). Isolation of human monoclonal antibodies that potently neutralize HCMV infection by targeting different epitopes on the gH/gL/UL128-131A complex. J. Virol. 84, 1005-1013.
113. Machado C.M., Dulley F.L., Boas L.S., Castelli J.B., Macedo M.C., Silva R.L., et al. (2000). CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant. 26, 413-417. (Pubitemid 30649557)
114. Mattes F.M, Vargas A., Kopycinski J., Hainsworth E.G., Sweny P., Nebbia G., et al. (2008). Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am. J. Transplant. 8, 990-999. (Pubitemid 351537766)
115. Mengelle C., Sandres-Sauné K, Pasquier C., Rostaing L., Mansuy J.M., Marty M., et al. (2003). Automated extraction and quantification of human cytomegalovirus DNA in whole blood by real-time PCR assay. J. Clin. Microbiol. 41, 3840-3845. (Pubitemid 36994724)
116. + gammadelta T cells play protective roles at an early phase of murine cytomegalovirus infection through production of interferon-gamma. Immunology. 99, 187-194. (Pubitemid 30093662)
117. + T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J. Clin. Immunol. 23, 247-257. (Pubitemid 36870667)
118. Pang X.L., Fox J.D., Fenton J.M., Miller G.G., Caliendo A.M., Preiksaitis J.K. (2009). Interlaboratory comparison of cytomegalovirus viral load assays. Am. J. Transplant. 9, 258-268.
119. Parente F., Bianchi Porro G., and The Italian Cytomegalovirus Study Group. (1998). Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a random-ized controlled study of foscarnet versus ganciclovir. Am. J. Gastroenterol. 93, 317-322. (Pubitemid 29068328)
120. Pastore D, Delia M, Mestice A., Perrone T., Carluccio P., Gaudio F., et al. (2011). Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation. Biol. Blood Marrow Transplant. 17, 550-557.
121. Pawelec G., Akbar A., Caruso C., Solana R, Grubeck-Loebenstein B, Wikby A. (2005). Human im-munosenescence: is it infectious? Immunol. Rev. 205, 257-268.
122. Pietersma F.L., Van Dorp S., Jacobi R., Ran L., Nanlohy N.M., Schuurman R., et al. (2010). High level of perforin expression in T cells: an early prognostic marker of the severity of herpesvirus reactivation after allogeneic stem cell transplantation in adults. Clin. Infect. Dis. 50, 717-725.
123. Piiparinen H., Höckerstedt K., Grönhagen-Riska C., Lautenschlager I. (2004). Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J. Clin. Virol. 30, 258-266. (Pubitemid 38622010)
124. PoLic B., Hengel H., Krmpotic A., Trgovcich J., Pavic I., Luccaronin P., et al. (1998). Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 188, 1047-1054. (Pubitemid 28443328)
125. + T-cell repertoire. J. Virol. 81, 7759- 7765. (Pubitemid 47047862)
126. +T cell populations specific for persistent DNA viruses. J. Exp. Med. 202, 1349-1361. (Pubitemid 41668738)
127. Quinnan Jr G.V., Kirmani N., Rook A.H., Manischewitz J.F., Jackson L, Moreschi G., et al. (1982). Cytotoxic T cells in cytomegalovirus infection: HLA- restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 307, 7-13. (Pubitemid 12075446)
128. Radha R., Jordan S., Puliyanda D., Bunnapradist S., Petrosyan A., Amet N., et al. (2005). Cellular immune responses to cytomegalovirus in renal transplant recipients. Am. J. Transplant. 5, 110-117. (Pubitemid 40095134)
129. Rasmussen L., Matkin C., Spaete R, Pachl C., Merigan T.C. (1991). Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J. Infect. Dis. 164, 835-842.
130. Razonable R.R., Brown R.A., Wilson J., Groettum C., Kremers W., Espy M., et al. (2002). The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in trans-plant recipients with CMV disease. Transplantation. 73, 968-973. (Pubitemid 34252365)
131. Razonable R.R., Van Cruusen H., Brown R.A., Wilson J.A., Harmsen W.S., Wiesner R.H., et al. (2003). Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J. Infect. Dis. 187, 1801-1808. (Pubitemid 36667892)
132. Reischig T., Jindra P., Hes O., SvecovA M., Klaboch J., Treska V. (2008). Valacyclovir prophylaxis versuspreemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am. J. Transplant. 8, 69-77.
133. Reusser P., Riddell S.R., Meyers J.D., Greenberg RD. (1991). Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 78, 1373-1380.
134. Reusser R, Cathomas G., Attenhofer R., Tamm M., Thiel G. (1999). Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J. Infect. Dis. 180, 247-253. (Pubitemid 30256302)
135. Reusser P, Einsele H., Lee J., Volin L., Rovira M., Engelhard D., et al. (2002). Randomized multi- center trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 99, 1159-1164. (Pubitemid 34547067)
136. Revello M.G., Percivalle E., Zavattoni M., Parea M., Grossi P., Gerna G. (1989). Detection of human cytomegalovirus immediate early antigen in leukocytes as a marker of viremia in immunocompromised patients. J. Med. Virol. 29, 88-93. (Pubitemid 19282244)
137. Revello M.G., Percivalle E., Arbustini E., Pardi R., Sozzani S., Gerna G. (1998). In vitro generation of human cytomegalovirus pp65 antigenemia, viremia, and leukoDNAemia.Clin. Invest. 101, 2686- 2692. (Pubitemid 28294577)
138. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., Greenberg P.D. (1992). Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 257, 238- 241.
139. Ryckman B.J., Rainish B.L., Chase M.C., Borton J.A., Nelson J.A., Jarvis M.A., et al. (2008). Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J. Virol. 82, 60-70. (Pubitemid 350309123)
140. Sallusto F., Lanzavecchia A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus inter- leukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 1109-1118.
141. Sallusto F., Lenig D., Förster R., Lipp M., Lanzavecchia A. (1999). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401, 708-712.
142. Sanchez J.L., Kruger R.M., Paranjothi S., Trulock E.P., Lynch J.P., Hicks C., et al. (2001). Relationship of cytomegalovirus viral load in blood to pneumonitis in lung transplant recipients. Transplantation. 72, 733-735. (Pubitemid 32802762)
143. Scalzo A.A., Fitzgerald N.A., Wallace C.R., Gibbons A.E., Smart Y.C., Burton R.C., et al. (1992). The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J. Immunol. 149, 581-589.
144. Schleiss M.R., Bourne N., Stroup G., Bravo F.J., Jensen N.J., Bernstein D.I. (2004). Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified re-combinant glycoprotein B vaccine. J. Infect. Dis. 189, 1374-1381. (Pubitemid 38543585)
145. Sester M., Sester U., Gärtner B., Heine G., Girndt M., Mueller-Lantzsch N., et al. (2001). Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation. 71, 1287-1294. (Pubitemid 32507149)
146. Sester M., Sester U., Gärtner B.C., Girndt M., Meyerhans A., Köhler H. (2002). Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J. Am. Soc. Nephrol. 13, 2577-2584.
147. Sester U., Gärtner B.C., Wilkens H, Schwaab B., Wössner R., Kindermann I., et al. (2005). Differences in CMV-specific T-cell levels and longterm susceptibility to CMV infection after kidney, heart and lung transplantation. Am. J. Transplant. 5, 1483-1489. (Pubitemid 40839442)
148. Seu P., Winston DJ., Holt C.D., Kaldas F., Busuttil R.W. (1997). Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation. 64, 1614-1617. (Pubitemid 28047396)
149. Shlobin O.A., West E.E., Lechtzin N., Miller S.M., Borja M., Orens J.B., et al. (2006). Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J. Immunol. 176, 2625-2634. (Pubitemid 43201715)
150. Singh N., Wannstedt C., Keyes L, Wagener M.M., Gayowski T., Cacciarelli T-V. (2005). Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation. 79, 1428-1434. (Pubitemid 40734808)
151. Singh N. (2006a). Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J. Clin. Virol. 35, 474-477. (Pubitemid 43324850)
152. Singh N. (2006b). Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev. Med. Virol. 16, 281-287. (Pubitemid 44497309)
153. Small L.N., Lau J., Snydman D.R. (2006). Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin. Infect. Dis. 43, 869-880. (Pubitemid 44435514)
154. Snyder L.D., Médinas R., Chan C., Sparks S., Davis W.A., Palmer S.M., et al. (2011). Polyfunctional cy-tomegalovirus-specifíc immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am. J. Transplant. 11, 553-560.
155. Snydman D.R. (2009). Cytomegalovirus prevention strategies: the case for prophylaxis. Am. J. Transplant. 9, 1254.
156. Spivey J.F., Singleton D., Sweet S, Storch G.A., Hayashi R J., Huddleston C.B., et al. (2007). Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Pediatr. Transplant. 11, 312-318. (Pubitemid 46570137)
157. Stagno S., Pass R.F., Dworsky M.E., Henderson R.E., Moore E.G., Walton P.D., et al. (1982). Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N. Engl. J. Med. 306, 945-949. (Pubitemid 12112944)
158. Stern M., Elsässer H., Hönger G., Steiger J., Schaub S., Hess C. (2008). The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients. Am. J. Transplant. 8, 1312-1317. (Pubitemid 351763694)
159. Sun H.Y., Wagener M.M., Singh N. (2008). Prevention of posttransplant cytomegalovirus disease and related outcome with valganciclovir: a systematic review. Am. J. Transplant. 8, 2111-2118.
160. + T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202, 673-685. (Pubitemid 41248418)
161. Tabeta K., Georgel P., Janssen E., Du X., Hoebe K., Crozat K., et al. (2004). Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. USA. 101, 3516-3521. (Pubitemid 38338227)
162. + T cells during episodes of viral DNAemia in allogeneic stem cell transplant re-cipients: potential implications for the management of active CMV infection. J. Med. Virol. 82, 1208- 1215.
163. Trzonkowski P., Mysliwska J., Szmit E., Wieckiewicz J., Lukaszuk K., Brydak L.B., et al. (2003). Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination - an impact of immunosenescence. Vaccine. 21, 3826-3836. (Pubitemid 37338210)
164. Van Der Bu W., Torensma R., Van Son W.J., Anema J., Schirm J., Tegzess A.M., et al. (1988). Rapid im-munodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes.J. Med. Virol. 25, 179-188.
165. Venema H., Van Den Berg A.P., Van Zanten C., Van Son W.J., Van Der Giessen M, The T.H. (1994). Naturalkiller cell responses in renal transplant patients with cytomegalovirus infection. J. Med. Virol. 42, 188-192. (Pubitemid 24077563)
166. Verkruyse L.A., Storch G.A., Devine S.M., Dipersio J.F., Vu R. (2006). Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant. 37, 51-56. (Pubitemid 43135315)
167. + T-cell responses using QuantiFERON-CMV. Transpl. Infect. Dis. 9, 165-170. (Pubitemid 46669086)
168. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., et al. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038-1044.
169. Wang D., Shenk T. (2005). Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl. Acad. Sci. USA. 102, 18153-18158. (Pubitemid 41798517)
170. Westall G.R, Michaeudes A., Williams T.J., Snell G.I., Kotsimbos T.C. (2004). Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J. Infect. Dis. 190, 1076-1083. (Pubitemid 39186793)
171. + T-cell immunity. Am. J. Transplant. 8, 1749-1754.
172. + CTL clones revert from CD45ROhigh to CD45RAh¡8h in vivo: CD45RAhi8hCD8+ T cells comprise both naive and memory cells.Immunol. 162, 7080-7087. (Pubitemid 29277676)
173. Yeager A.S., Grumet F.C., Hafleigh E.B., Arvin A.M., Bradley J.S., Prober C.G. (1981). Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J. Pediatr. 98, 281-287. (Pubitemid 11191091)
174. Zambelli A., Lilleri D., Pedrazzoli P., Peccatori J., Baldanti F., Fregoni V., et al. (2005). Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmye- loablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic ma-lignancies. Biol. Blood Marrow Transplant. 11, 423-428. (Pubitemid 40753794)
175. Zedtwitz-Liebenstein K., Jaksch P., Bauer C., Popow T., Klepetko W, Hofmann H., Puchhammer-Stockl E. (2004). Association of cytomegalovirus DNA concentration in epithelial lining fluid and symptomatic cytomegalovirus infection in lung transplant recipients. Transplantation. 77, 1897- 1899. (Pubitemid 38822215)